IGF-1 LR3 for Dogs
Long R3 insulin-like growth factor 1
The short answer
IGF-1 LR3 demands more caution than anything else on this site apart from the investigational oncology compounds. Two risks are concrete rather than theoretical: it can lower blood glucose enough to cause tremors or collapse, and because IGF-1 signalling drives cell proliferation it is contraindicated in any dog with known or suspected cancer. The mandatory four-week off-cycle exists to let receptor sensitivity recover. Canine evidence is Level V — mechanistic and extrapolated, not clinical.
What it is and how it is thought to work
IGF-1 LR3 is a modified version of insulin-like growth factor 1, the hormone that mediates most of growth hormone's effects on muscle. The modification reduces how tightly it binds the carrier proteins that normally hold IGF-1 in circulation, leaving more of it free to reach the receptor. Protocols circulating online describe this as extending its active life to twenty or thirty hours, but no peer-reviewed pharmacokinetic study establishes that figure, and it sits awkwardly with the underlying pharmacology — binding to those carrier proteins is what normally protects IGF-1 from being cleared, so reducing that binding would be expected to shorten its time in circulation rather than lengthen it. What is not in doubt is that it signals more freely than native IGF-1, and that is the reason it demands the most caution of any compound here.
Mechanism in clinical terms
Reduced affinity for IGF binding proteins leaves a greater free fraction available to the receptor. The 20-30 hour terminal half-life widely quoted for this analogue has no peer-reviewed pharmacokinetic study behind it, and it runs counter to the established relationship: free IGF-1 has a half-life of roughly 10-15 minutes, IGFBP-3-associated IGF-1 approximately 10-16 hours, and deliberately complexing IGF-1 with IGFBP-3 extends it further still. Reducing IGFBP affinity would therefore be expected to accelerate clearance, not slow it. Treat the circulating figure as unverified. Investigated for muscle protein synthesis and satellite cell activation. Level V evidence in the canine context.
Canine dosing by weight class
Figures below are reported as they appear in the source literature. They are not recommendations, and dosing for an individual dog must be set by a veterinarian.
Small / toy breed
under 22 lb (10 kg)
- Reported dose
- 2–40 mcg per day
- Frequency
- Once daily
- Duration
- 4-6 weeks, then 4 weeks off
- Studied for
- Muscle wasting, post-surgical recovery
Medium breed
22–77 lb (10–35 kg)
- Reported dose
- 10–100 mcg per day
- Frequency
- Once daily
- Duration
- 4-6 weeks, then 4 weeks off
- Studied for
- Muscle wasting, sarcopenia, post-surgical recovery
Large / giant breed
over 77 lb (35 kg)
- Reported dose
- 35–100 mcg per day
- Frequency
- Once daily
- Duration
- 4-6 weeks, then 4 weeks off
- Studied for
- Sarcopenia, muscle loss in senior dogs
Need a figure for a specific weight? Use the dose calculator, or see the weight-specific pages: small / toy breed, medium breed, large / giant breed.
Contraindications and warnings
Read these before anything else on the page.
⚠ Contraindicated with active cancer
IGF-1 signalling directly drives cell proliferation. In a dog with an existing malignancy that is precisely the wrong signal. Screening before use is mandatory, not advisory.
⚠ Hypoglycaemia risk
IGF-1 LR3 has insulin-like activity and can lower blood glucose. Tremors, disorientation, weakness, or collapse are emergencies. Blood glucose must be monitored, and diabetic dogs require direct veterinary management.
Do not stack with MGF
MGF is a splice variant of the same gene and acts on overlapping pathways. Running both simultaneously compounds growth signalling without a clear rationale.
Example research protocol
A representative timeline drawn from the published literature, showing what is monitored and when. Any actual protocol should be set by the veterinarian managing the case.
- 1Week 1Conservative start
What owners observe
Start at the bottom of the range. Watch for lethargy, tremors, or unusual hunger, which can indicate low blood sugar. Feed normally and do not fast your dog around injection times.
Clinical monitoring
Begin at 1 mcg/kg/day subcutaneously. Check fasting glucose at baseline and day 7. The extended half-life means sustained signalling rather than a short pulse.
- 2Weeks 2-4Titrate to target
What owners observe
Improved muscle mass and definition in wasting patients, with more energy and activity. An appetite increase is expected. Weigh weekly.
Clinical monitoring
Increase toward 2-4 mcg/kg/day if tolerated. Muscle protein synthesis and satellite cell activation expected during this window. Recheck glucose at weeks 2 and 4. Assess for organ hypertrophy.
- 3Week 5 onwardMandatory off-cycle
What owners observe
Stop for a minimum of four weeks. Gains from the first cycle should largely hold. Keep exercise and nutrition consistent and note any regression.
Clinical monitoring
The off-cycle allows IGF-1 receptor sensitivity to normalise. Recheck glucose. A maximum of three cycles is the conventional ceiling.
What IGF-1 LR3 is investigated for
Muscle wasting
Loss of muscle mass from age, disuse, chronic illness, or prolonged rest after injury.
Post-surgical recovery
Supporting tissue repair, comfort, and return to function after an orthopaedic or soft tissue procedure.
Senior dog mobility
The combined effect of arthritis, muscle loss, and reduced activity that limits older dogs.
How it compares
- IGF-1 LR3 vs MGF for dogs — how IGF-1 LR3 differs from MGF
- BPC-157 vs IGF-1 LR3 for dogs — how IGF-1 LR3 differs from BPC-157
Common questions
Is IGF-1 LR3 safe for dogs?+
IGF-1 LR3 demands more caution than anything else on this site apart from the investigational oncology compounds. Two risks are concrete rather than theoretical: it can lower blood glucose enough to cause tremors or collapse, and because IGF-1 signalling drives cell proliferation it is contraindicated in any dog with known or suspected cancer. The mandatory four-week off-cycle exists to let receptor sensitivity recover. Canine evidence is Level V — mechanistic and extrapolated, not clinical.
How much IGF-1 LR3 should I give my dog?+
Reported doses vary by weight class. Small / toy breed (under 22 lb (10 kg)): 2–40 mcg per day, once daily. Medium breed (22–77 lb (10–35 kg)): 10–100 mcg per day, once daily. Large / giant breed (over 77 lb (35 kg)): 35–100 mcg per day, once daily. These figures are reported as they appear in the source literature and are not recommendations — dosing for an individual dog must be set by a veterinarian who has examined the animal.
How is IGF-1 LR3 given to dogs?+
IGF-1 LR3 is administered by subcutaneous injection or intramuscular injection. See the injection guide and reconstitution guide for handling detail.
What is the evidence for IGF-1 LR3 in dogs?+
IGF-1 LR3 is graded as preliminary evidence on this site, drawing on 2 cited studies. IGF-1 LR3 is a modified version of insulin-like growth factor 1, the hormone that mediates most of growth hormone's effects on muscle. The modification reduces how tightly it binds the carrier proteins that normally hold IGF-1 in circulation, leaving more of it free to reach the receptor. Protocols circulating online describe this as extending its active life to twenty or thirty hours, but no peer-reviewed pharmacokinetic study establishes that figure, and it sits awkwardly with the underlying pharmacology — binding to those carrier proteins is what normally protects IGF-1 from being cleared, so reducing that binding would be expected to shorten its time in circulation rather than lengthen it. What is not in doubt is that it signals more freely than native IGF-1, and that is the reason it demands the most caution of any compound here.
References
- 1.Goldspink G Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology, 2005. PMID 16024511
- 2.Kandalla PK, Goldspink G, Butler-Browne G, Mouly V Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mechanisms of Ageing and Development, 2011. PMID 21354439
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.